A Double-blind, Placebo-Controlled Fixed-Dose Study of Vilazodone in Patients With Generalised Anxiety Disorder.
Phase of Trial: Phase III
Latest Information Update: 24 May 2017
At a glance
- Drugs Vilazodone (Primary)
- Indications Generalised anxiety disorder
- Focus Therapeutic Use
- Sponsors Forest Laboratories
- 06 Mar 2014 According to ClinicalTrials.gov record, status changed from active, no longer recruiting to completed.
- 15 Nov 2013 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 26 Jul 2012 Actual initiation date (June 2012) added as reported by ClinicalTrials.gov.